Literature DB >> 7887433

Prenatal genetic counseling for hemoglobinopathy carriers: a comparison of primary providers of prenatal care and professional genetic counselors.

P T Rowley1, S Loader, C J Sutera, A Kozyra.   

Abstract

Health personnel trained in medical genetics are insufficient to meet the demand for genetic services. Methods must be found to enable primary care providers to offer commonly needed genetic services themselves. In our recently reported community-wide prenatal screening program for hemoglobinopathies, 36% of women detected to have a hemoglobinopathy did not come to a tertiary center for counseling and thus may have not benefited from testing. To determine whether the efficiency of the program could be increased if counseling were provided by the prenatal care provider (obstetrician or family practitioner), we developed a pilot training program on the basis of our experience in offering such services and enlisted 68% of regional prenatal care providers to participate. The proportion of patients detected to have a hemoglobinopathy who received counseling was similar in the primary and tertiary provider groups: 59% versus 50%, respectively, for sickle trait, and 69% versus 66%, respectively, for beta-thalassemia trait. Knowledge after counseling was also similar for the primary and tertiary provider groups: 64% versus 66% (mean % correct), respectively, for sickle trait, and 79% versus 78%, respectively, for beta-thalassemia trait. However, the two provider groups significantly differed with regard to whether or not the patient had her partner tested. For sickle trait, it was 25% for the primary providers but 49% for the tertiary providers (P < .001). For beta-thalassemia trait, it was 47% for the primary providers but 78% for the tertiary providers (P < .001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7887433      PMCID: PMC1801185     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  15 in total

1.  THE "WHOLE FAMILY" CONCEPT IN CLINICAL GENETICS.

Authors:  R L TIPS; G S SMITH; H T LYNCH; C W MCNUTT
Journal:  Am J Dis Child       Date:  1964-01

2.  Stigmatization of carrier status: social implications of heterozygote genetic screening programs.

Authors:  R H Kenen; R M Schmidt
Journal:  Am J Public Health       Date:  1978-11       Impact factor: 9.308

3.  Cuban programme for prevention of sickle cell disease.

Authors:  H Granda; S Gispert; A Dorticós; M Martín; Y Cuadras; M Calvo; G Martínez; M A Zayas; J A Oliva; L Heredero
Journal:  Lancet       Date:  1991-01-19       Impact factor: 79.321

4.  Screening and genetic counseling for beta-thalassemia trait in a population unselected for interest: comparison of three counseling methods.

Authors:  P T Rowley; M Lipkin; L Fisher
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

5.  Prenatal diagnosis of sickle hemoglobinopathies: the experience of the Columbia University Comprehensive Center for Sickle Cell Disease.

Authors:  M C Driscoll; N Lerner; K Anyane-Yeboa; J Maidman; D Warburton; K Schaefer-Rego; R Hsu; C Ince; J Malin; M Pallai
Journal:  Am J Hum Genet       Date:  1987-06       Impact factor: 11.025

Review 6.  The diffusion of new genetic tests for predicting disease.

Authors:  N A Holtzman
Journal:  FASEB J       Date:  1992-07       Impact factor: 5.191

7.  Prediction and diagnosis of sickling disorders in neonates.

Authors:  N Adjaye; B J Bain; P Steer
Journal:  Arch Dis Child       Date:  1989-01       Impact factor: 3.791

8.  Prenatal hemoglobinopathy screening. IV. Follow-up of women at risk for a child with a clinically significant hemoglobinopathy.

Authors:  S Loader; C J Sutera; S G Segelman; A Kozyra; P T Rowley
Journal:  Am J Hum Genet       Date:  1991-12       Impact factor: 11.025

9.  Prenatal screening for hemoglobinopathies. II. Evaluation of counseling.

Authors:  S Loader; C J Sutera; M Walden; A Kozyra; P T Rowley
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

10.  Prenatal screening for hemoglobinopathies. I. A prospective regional trial.

Authors:  P T Rowley; S Loader; C J Sutera; M Walden; A Kozyra
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.